Comparative Pharmacology
Head-to-head clinical analysis: CHOLETEC versus OMNIPAQUE 70.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHOLETEC versus OMNIPAQUE 70.
CHOLETEC vs OMNIPAQUE 70
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Choletec is a technetium-99m labeled iminodiacetic acid derivative used for hepatobiliary scintigraphy. It is taken up by hepatocytes via organic anion transporting polypeptides and excreted into bile canaliculi via multidrug resistance-associated protein 2, allowing visualization of the biliary system.
Iodinated contrast agent that attenuates X-rays, enhancing vascular and tissue contrast by increasing the density of blood vessels and organs.
1 gram intravenously every 8 hours; maximum 3 g/day.
1.5-2.0 mL/kg IV for contrast enhanced CT, max 150 mL; intra-arterial: 5-40 mL per injection depending on procedure.
None Documented
None Documented
Terminal elimination half-life is approximately 16–24 hours; clinically, once-daily dosing achieves steady-state after 5–7 days, allowing for pharmacological effects on bile acid composition.
Terminal elimination half-life: 1-2 hours in normal renal function; prolonged in renal impairment (up to 20-30 hours in severe dysfunction).
Primarily biliary (approx. 50–70% as unchanged drug and metabolites) with fecal elimination; renal excretion is minimal (<5% unchanged).
Renal: 100% unchanged via glomerular filtration. No biliary or fecal elimination.
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent